Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications

Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh

doi:10.1016/j.drudis.2016.07.004

Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications

Drug Discov Today. 2016 Oct;21(10):1711-1718. doi: 10.1016/j.drudis.2016.07.004. Epub 2016 Jul 12.

Authors

Yosuke Hashimoto¹, Kiyohito Yagi¹, Masuo Kondoh²

Affiliations

¹ Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan.
² Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871, Japan. Electronic address: masuo@phs.osaka-u.ac.jp.

PMID: 27422269
DOI: 10.1016/j.drudis.2016.07.004

Abstract

Claudins (CLDNs) are a 27-member family of tetra-transmembrane proteins that have pivotal roles in maintaining cellular polarity and sealing the spaces between adjacent cells. Deregulation of their functions is often associated with pathological conditions, including carcinogenesis and inflammation. Some CLDNs are co-receptors for hepatitis C virus. Because CLDN-driven regulation of intercellular seals might be manipulated to enhance drug absorption, CLDNs are attractive targets for drug development. Monoclonal antibodies recognizing the extracellular domain of CLDNs are the first choice for therapeutics, but their development has been delayed. Here, we overview recent advances in the creation of anti-CLDN antibodies and discuss CLDNs as drug development targets.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Monoclonal* / pharmacology
Antibodies, Monoclonal* / therapeutic use
Claudins / immunology*
Claudins / metabolism
Drug Design
Humans

Substances

Antibodies, Monoclonal
Claudins